BeOne Medicines Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
299.01
-2.12 (-0.70%)
Aug 1, 2025, 4:00 PM - Market closed

ATSG Statistics

Total Valuation

BeOne Medicines has a market cap or net worth of $35.48 billion. The enterprise value is $33.96 billion.

Market Cap35.48B
Enterprise Value 33.96B

Important Dates

The next confirmed earnings date is Wednesday, August 6, 2025, before market open.

Earnings Date Aug 6, 2025
Ex-Dividend Date n/a

Share Statistics

BeOne Medicines has 118.65 million shares outstanding. The number of shares has increased by 1.47% in one year.

Current Share Class n/a
Shares Outstanding 118.65M
Shares Change (YoY) +1.47%
Shares Change (QoQ) +4.62%
Owned by Insiders (%) 4.28%
Owned by Institutions (%) 44.79%
Float 75.76M

Valuation Ratios

PE Ratio n/a
Forward PE 154.19
PS Ratio 7.59
Forward PS 1.94
PB Ratio 9.22
P/TBV Ratio 10.29
P/FCF Ratio n/a
P/OCF Ratio 167.33
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 8.13
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.28.

Current Ratio 1.96
Quick Ratio 1.64
Debt / Equity 0.28
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -15.99

Financial Efficiency

Return on equity (ROE) is -11.44% and return on invested capital (ROIC) is -4.16%.

Return on Equity (ROE) -11.44%
Return on Assets (ROA) -3.22%
Return on Invested Capital (ROIC) -4.16%
Return on Capital Employed (ROCE) -7.69%
Revenue Per Employee $379,624
Profits Per Employee -$35,670
Employee Count11,000
Asset Turnover 0.73
Inventory Turnover 1.35

Taxes

In the past 12 months, BeOne Medicines has paid $123.69 million in taxes.

Income Tax 123.69M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +79.50% in the last 52 weeks. The beta is 0.28, so BeOne Medicines's price volatility has been lower than the market average.

Beta (5Y) 0.28
52-Week Price Change +79.50%
50-Day Moving Average 263.52
200-Day Moving Average 232.53
Relative Strength Index (RSI) 65.33
Average Volume (20 Days) 430,030

Short Selling Information

The latest short interest is 1.62 million, so 1.37% of the outstanding shares have been sold short.

Short Interest 1.62M
Short Previous Month 1.80M
Short % of Shares Out 1.37%
Short % of Float 2.14%
Short Ratio (days to cover) 4.77

Income Statement

In the last 12 months, BeOne Medicines had revenue of $4.18 billion and -$392.37 million in losses. Loss per share was -$3.70.

Revenue4.18B
Gross Profit 3.54B
Operating Income -296.56M
Pretax Income n/a
Net Income -392.37M
EBITDA -122.01M
EBIT -296.56M
Loss Per Share -$3.70
Full Income Statement

Balance Sheet

The company has $2.52 billion in cash and $996.83 million in debt, giving a net cash position of $1.52 billion or $12.81 per share.

Cash & Cash Equivalents 2.52B
Total Debt 996.83M
Net Cash 1.52B
Net Cash Per Share $12.81
Equity (Book Value) 3.50B
Book Value Per Share 32.42
Working Capital 1.91B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $212.02 million and capital expenditures -$392.49 million, giving a free cash flow of -$180.47 million.

Operating Cash Flow 212.02M
Capital Expenditures -392.49M
Free Cash Flow -180.47M
FCF Per Share -$1.52
Full Cash Flow Statement

Margins

Gross margin is 84.81%, with operating and profit margins of -7.10% and -9.40%.

Gross Margin 84.81%
Operating Margin -7.10%
Pretax Margin -6.43%
Profit Margin -9.40%
EBITDA Margin -2.92%
EBIT Margin -7.10%
FCF Margin n/a

Dividends & Yields

BeOne Medicines does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -1.47%
Shareholder Yield -1.47%
Earnings Yield -1.11%
FCF Yield -0.51%

Analyst Forecast

The average price target for BeOne Medicines is $332.44, which is 11.18% higher than the current price. The consensus rating is "Strong Buy".

Price Target $332.44
Price Target Difference 11.18%
Analyst Consensus Strong Buy
Analyst Count 9
Revenue Growth Forecast (5Y) 75.41%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

BeOne Medicines has an Altman Z-Score of 4.11 and a Piotroski F-Score of 5.

Altman Z-Score 4.11
Piotroski F-Score 5